Ethaverine hydrochloride
目录号 : GC74193Ethaverine hydrochloride罂粟碱的衍生物,抑制心脏L型钙通道。
Cas No.:985-13-7
Sample solution is provided at 25 µL, 10mM.
Ethaverine drochloride, a derivative of papaverine, inhibits cardiac L-type calcium channel. Ethaverine drochloride is a peripheral vasodilator and antispasmodic agent. Ethaverine drochloride can be used for research of peripheral vascular disease.
Ethaverine drochloride (10 μM, PC12 cells) reduces catecholamine secretion by blocking the L-type voltage-sensitive Ca2+ channel[2].Ethaverine drochloride (12 h) decreases dopamine content by inhibiting tyrosine droxylase (TH) activity in PC12 cells, with an IC50 of 1.4 μM[3].Ethaverine drochloride inhibits monoamine oxidase (MAO) activity in mouse brain (isolated from mouse whole brain), with an IC50 of 25.5 μM[6].
Ethaverine drochloride (2-10 mg/kg, intravenous infusion, i.v.) causes significant elevation of endocochlear potential in guinea pigs[4].Ethaverine (1-10 mg/kg, i.v.) inhibits atrioventricular conduction and heart rate in the anaesthetized dog[5].
References:
[1]. Wang Y, et al. Ethaverine, a derivative of papaverine, inhibits cardiac L-type calcium channels. Mol Pharmacol. 1991 Nov;40(5):750-5.
[2]. Suh BC, et al. Inhibition by ethaverine of catecholamine secretion through blocking L-type Ca2+ channels in PC12 cells. Biochem Pharmacol. 1994 Mar 29;47(7):1262-6.
[3]. Shin JS, et al. Inhibitory effects of ethaverine, a homologue of papaverine, on dopamine content in PC12 cells. Biol Pharm Bull. 2001 Jan;24(1):103-5.
[4]. Prazma J, et al. Effect of ethaverine drochloride on cochlear microcirculation. Arch Otolaryngol. 1981 Apr;107(4):227-9.
[5]. Lacroix P, et al. [Comparative activity of ethaverine and papaverine on chronotropic and dromotropic cardiac functions in the anesthetized dog]. Arch Int Pharmacodyn Ther. 1976 May;221(1):163-76. French.
[6]. Lee SS, et al. Inhibitory effects of ethaverine, a homologue of papaverine, on monoamine oxidase activity in mouse brain. Biol Pharm Bull. 2001 Jul;24(7):838-40.
Cas No. | 985-13-7 | SDF | |
分子式 | C24H30ClNO4 | 分子量 | 431.95 |
溶解度 | 储存条件 | ||
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 2.3151 mL | 11.5754 mL | 23.1508 mL |
5 mM | 0.463 mL | 2.3151 mL | 4.6302 mL |
10 mM | 0.2315 mL | 1.1575 mL | 2.3151 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch: